The DOI matches its Crossref record; 152 of the 158 references it cites were found in a registry or an index; 92 of the 144 sources its claims cite were checked for support.
Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma
Open accessAbstract
Malignant pleural mesothelioma (MPM) is a lethal and rare cancer, even if its incidence has continuously increased all over the world. Asbestos exposure leads to the development of mesothelioma through multiple mechanisms, including chronic inflammation, oxidative stress with reactive oxygen species (ROS) generation, and persistent aberrant signaling. Together, these processes, over the years, force normal mesothelial cells’ transformation. Chronic inflammation supported by “frustrated” macrophages exposed to asbestos fibers is also boosted by the release of pro-inflammatory cytokines, chemokines, growth factors, damage-associated molecular proteins (DAMPs), and the generation of ROS. In addition, the hypoxic microenvironment influences MPM and immune cells’ features, leading to a significant rewiring of metabolism and phenotypic plasticity, thereby supporting tumor aggressiveness and modulating infiltrating immune cell responses. This review provides an overview of the complex tumor–host interactions within the MPM tumor microenvironment at different levels, i.e., soluble factors, metabolic crosstalk, and oxidative stress, and explains how these players supporting tumor transformation and progression may become potential and novel therapeutic targets in MPM.
Overview
CoChat Summary
TL;DR
This review synthesizes how chronic inflammation, oxidative stress/ROS, and metabolic plasticity jointly drive a pro-tumorigenic, immunosuppressive microenvironment in malignant pleural mesothelioma (MPM). It highlights candidate therapeutic targets including TGF-β, IL-6, TNF-α/HMGB1, redox-sensitive factors, the adenosine pathway, and BAP1-related metabolic reprogramming.
Key findings
- Asbestos-induced “frustrated phagocytosis” by macrophages causes ROS release, pro-inflammatory cytokines/chemokines (IL-8, IL-6, CCL2/MCP-1, G-CSF, GM-CSF, MIP-1α), DAMPs including HMGB1, and chronic inflammation that promotes mesothelial transformation; M2-like macrophages (CD163+, CD206+, IL-4Rα+) infiltrate MPM.
- TGF-β family members (gremlin-1, activin A, TGF-β) support MPM progression; TGF-β1 mRNA correlated with worst prognosis in 74 mesothelioma tumors. In a fresolimumab trial, no radiographic responses were observed, median progression time was 1.4 months, and 10 patients progressed after only two cycles. IL-6 is produced by mesothelioma cells, but its autocrine growth role is conflicting; it may mediate resistance to classic cytotoxic agents.
- Oxidative stress/ROS from asbestos iron content and inflammatory cells activates antioxidant pathways involving Nrf2, Ref-1, and FOXM1; a ROS–TGF-β1 axis promotes EMT, and iron/ferritin biology (FHC, FTL) plus ferroptosis resistance are implicated in asbestos-related carcinogenesis.
- Metabolic plasticity includes hypoxia-driven GLUT-1/HIF-1α/VEGF/PI3K-mTOR upregulation, LAT1-mediated amino acid deprivation of T cells, IDO-mediated tryptophan degradation, adenosine/CD39/CD73 signaling, and BAP1 loss shifting metabolism from TCA/OXPHOS toward aerobic glycolysis with increased extracellular lactate.
Methods
- Narrative review; no primary experiments, systematic search strategy, or meta-analysis are described. It synthesizes published literature on MPM tumor–host interactions, soluble factors, oxidative stress, and metabolic crosstalk.
- Evidence cited includes preclinical models, mesothelioma cell lines, patient pleural effusions/tumors, and clinical trials such as CheckMate 743 and a fresolimumab study. No sample size or literature-search details are stated.
Limitations
- The paper does not state a formal limitations section. Stated caveats include conflicting results on IL-6 as an autocrine growth factor, very little information about the adenosine pathway in MPM, and significant intra-tumoral and inter-tumoral heterogeneity between patients.
- Evident from the text: as a narrative review, it lacks systematic search and quality appraisal, and many mechanistic conclusions rely on heterogeneous preclinical or non-MPM findings; therapeutic targeting of these pathways remains largely speculative.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
61 Valid · 4 Not valid · 28 Not checked · 25 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Mechanistically, longer fibers cannot be effectively phagocytized by macrophages.”
§ Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma > 1. Introduction
What the sources say
- Supportedcites [18] Nagai, 2011, Asbestos Surface Provides a Niche for Oxidative Modification, Cancer Sci. source
The passage labeled Abstract states that long asbestos fibers, especially those over 15–20 μm, interrupt macrophage phagocytosis and prevent macrophages from clearing the fibers. This supports the citing sentence. (LLM, conf=0.94)
- Supportedcites [19] Gaudino, 2020, How Asbestos and Other Fibers Cause Mesothelioma, Transl. Lung Cancer Res. source
The section “Physicochemical features of the fibers govern their carcinogenic potential” states that longer fibers cannot be efficiently engulfed and cleared by macrophages, leading to failed attempts at phagocytosis. This directly supports the citing sentence’s paraphrase. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, chronic inflammation is the main factor underlying the pathogenesis of MPM induced by asbestos, leading to malignant mesothelial cell transformation.”
§ Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma > 1. Introduction
What the sources say
- Partly supportedcites [18] Nagai, 2011, Asbestos Surface Provides a Niche for Oxidative Modification, Cancer Sci. sourceExperimental — accuracy not yet measured
The Abstract (page not specified) links chronic inflammation to asbestos-induced genotoxicity in mesothelial cells and says an inflammatory cytokine might increase the likelihood of transformation. But it presents inflammation as one of several proposed mechanisms, alongside mesothelial cell injury, rather than establishing it as the main factor in MPM pathogenesis. (LLM, conf=0.86)
- Partly supportedcites [19] Gaudino, 2020, How Asbestos and Other Fibers Cause Mesothelioma, Transl. Lung Cancer Res. sourceExperimental — accuracy not yet measured
The ‘Chronic inflammation and mesothelioma’ section says chronic inflammation plays a major role in asbestos-induced pathogenesis and describes a pathway to mesothelial-cell transformation. It does not establish inflammation as the single main factor, rather than one major mechanism among others. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“TGF-β1 plays a crucial role in promoting EMT, a key process involved in modulating alveolar epithelial cell plasticity [87,88].”
§ Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma > 3. Mesothelioma Microenvironment: Tumor–Host Crosstalk Driving Chronic Inflammation > 3.2. Oxidative Stress and ROS
What the sources say
- Not checked — no full text of the sourcecites [87] Tamminen, 2012, Asbestos Exposure Induces Alveolar Epithelial Cell Plasticity through MAPK/Erk Signaling, J. Cell. Biochem. source
- Partly supportedcites [88] Tsubakihara, Y., and Moustakas, A. (2018). Epithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor β. Int. J. Mol. Sci., 19. sourceExperimental — accuracy not yet measured
Section 2, “Regulation of EMT by TGF-β,” says TGF-β plays a prominent role in inducing EMT and specifies that its discussion includes TGF-β1. The Introduction describes EMT as a form of epithelial-cell plasticity, but the paper’s passages concern cancer and do not establish the claim specifically for alveolar epithelial cells. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“It has been described that extracellular ROS regulate the TGF-β axis [66,84,85].”
§ Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma > 3. Mesothelioma Microenvironment: Tumor–Host Crosstalk Driving Chronic Inflammation > 3.2. Oxidative Stress and ROS
What the sources say
- Supportedcites [66] Urso, 2020, Metabolic Rewiring and Redox Alterations in Malignant Pleural Mesothelioma, Br. J. Cancer source
The section “Effects of ROS on TGF-β in MPM” states that ROS in the extracellular space can activate TGF-β. It also describes an in vitro example in which ROS generated by asbestos-associated iron activated TGF-β1, supporting the attributed claim. (LLM, conf=0.94)
- Not matchedcites [84] Santibanez, 2015, Transforming Growth Factor-Beta and Oxidative Stress Interplay: Implications in Tumorigenesis and Cancer Progression, Oxid. Med. Cell. Longev.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [85] Jobling, 2006, Isoform-Specific Activation of Latent Transforming Growth Factor β (LTGF-β) by Reactive Oxygen Species, Radiat. Res. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As previously mentioned in this review, TGF-β itself and its family members have been recognized to be involved in cancer development [81], and TGF-β possesses a pro-oncogenic role in MPM connected to immune suppression [82,83].”
§ Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma > 3. Mesothelioma Microenvironment: Tumor–Host Crosstalk Driving Chronic Inflammation > 3.2. Oxidative Stress and ROS
What the sources say
- Not checked — no full text of the sourcecites [82] Suzuki, 2004, Soluble Type II Transforming Growth Factor-Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity, Clin. Cancer Res. source
- Partly supportedcites [83] Fujii, 2012, TGF-β Synergizes with Defects in the Hippo Pathway to Stimulate Human Malignant Mesothelioma Growth, J. Exp. Med. sourceExperimental — accuracy not yet measured
The Abstract reports pro-oncogenic effects of TGF-β signaling in malignant mesothelioma. The Discussion proposes that TGF-β produced by mesothelioma tumors might suppress immune responses in the surrounding environment, but does not establish immune suppression as the mechanism of its pro-oncogenic effect. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [81] Derynck, 2001, TGF-β Signaling in Tumor Suppression and Cancer Progression, Nat. Genet. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
65 more claims · 29 with their cited sources checked
Create a free account to see all 118 claims and every source verdict.
- It may state two separate claims as one. 46
- Probably not a substantial claim. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“demonstrated that these redox-sensitive transcription factors that can counteract MPM chronic oxidative stress can therefore be considered as predictive biomarkers of MPM and potential pharmacological targets in the treatment of MPM [80].”
Cited work 10.3390/cancers13051138 · retracted 2021-03-07 · notice 10.3390/cancers18162564 · this paper published 2023-08-11
Citations
Cites
1 retracted
Schiavello, M., Gazzano, E., Bergandi, L., Silvagno, F., Libener, R., Riganti, C., & Aldieri, E. (2021) · Cancers · doi:10.3390/cancers13051138 · Cited by 8 · cited 1×
“demonstrated that these redox-sensitive transcription factors that can counteract MPM chronic oxidative stress can therefore be considered as predictive biomarkers of MPM and potential pharmacological targets in the treatment of MPM [80].”
BackgroundRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“ROS, which are produced by cancer cells and non-cancer cells within the microenvironment, are essential elements connecting metabolic reprogramming/oxidative stress/inflamed environment, all of which are key aspects of cancer progression [70].”
BackgroundHallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887 · cited 5×
“In normal cells, most energy is derived via oxidative respiration (i.e., the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS)).”
BackgroundInfluentialHow mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207 · cited 2×
“In turn, TGF-β can promote ROS production via the ETC [91] and downregulate the expression of antioxidant enzymes [84], suggesting a circuit of positive mutual regulation.”
BackgroundWhy Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 5×
“In normal cells, most energy is derived via oxidative respiration (i.e., the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS)).”
BackgroundInfluentialInflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806 · cited 1×
“Furthermore, another important kind of inflammation is therapy-induced inflammation, which progresses in response to various anti-neoplasm therapies, including radiotherapy, chemotherapy, and, recently, immunotherapies or biologic therapies, leading to a huge infiltration of immune cells [23].”
BackgroundROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis
D'Autréaux, B., & Toledano, M. B. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2256 · Cited by 3,642
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579 · cited 1×
“This axis could be pharmacologically targeted, opening up a possibility for novel combination therapy [92].”
BackgroundReactive oxygen species, cellular redox systems, and apoptosis
Circu, M. L., & Aw, T. Y. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.12.022 · Cited by 3,340 · cited 1×
“ROS are highly chemically reactive molecules, derived from the deficient reduction in molecular oxygen (O2) and playing a critical role as signaling molecules in tumorigenesis [68], including asbestos-mediated carcinogenesis [15,66,69].”
BackgroundVogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060 · cited 1×
“The use of surgery in patients with MPM is very limited, the only approved therapy regimen includes pemetrexed plus cisplatin, and there is no standard second-line treatment [3,4].”
BackgroundFunctional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
Hayes, J. D., Dinkova-Kostova, A. T., & Tew, K. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.001 · Cited by 2,654 · cited 6×
“GSH is often overexpressed by cancer cells to overcome ROS accumulation [67,75] Cells also have catalytic antioxidants able to scavenge the superoxide anion O2·, converted into hydrogen peroxide (H2O2) by the cytosolic copper/zinc superoxide dismutases (SOD) 1 and 2, localized in the cytosol and mitochondria, respecti…”
BackgroundInfluentialTGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275 · cited 1×
“As previously mentioned in this review, TGF-β itself and its family members have been recognized to be involved in cancer development [81], and TGF-β possesses a pro-oncogenic role in MPM connected to immune suppression [82,83].”
BackgroundTargeting Ferroptosis as a Vulnerability in Cancer
Lei, G., Zhuang, L., & Gan, B. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00459-0 · Cited by 2,252 · cited 1×
“On the contrary, ferroptosis evasion and resistance may contribute to tumor initiation and progression [97].”
BackgroundROS in cancer therapy: the bright side of the moon
Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0384-2 · Cited by 2,176 · cited 3×
“carotene vitamin E and C, and plant polyphenols, which can participate in the ROS scavenging process [67,74].”
BackgroundCancer metabolism: looking forward
Martínez-Reyes, I., & Chandel, N. S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,824
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Gong, T., Liu, L., Jiang, W., & Zhou, R. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0215-7 · Cited by 1,672 · cited 1×
“Initially, DAMPs were considered to be released only from necrotic cells, while new findings support the evidence that immunogenic cell death and necroptosis can trigger DAMPs’ release from cytosol into the extracellular space [56].”
BackgroundA decade of immune-checkpoint inhibitors in cancer therapy
Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608 · cited 1×
“In recent years, several new therapeutic strategies have been explored, the most promising being immune checkpoint inhibitors (ICIs), blocking the programmed cell death protein 1/programmed cell death1 ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), which are currently the standard of care for man…”
BackgroundBaas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215 · cited 1×
“subtype, suggesting a potential use as a first line in the future [9].”
BackgroundCorzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Metabolism of Inflammation Limited by AMPK and Pseudo-Starvation
O'Neill, L. A. J., & Hardie, D. G. (2013) · Nature · doi:10.1038/nature11862 · Cited by 1,133
Tumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096 · cited 1×
“Additionally, TAMs–MPM crosstalk underlies the acquisition of the immunosuppressive and chemoresistant phenotype [32].”
BackgroundGermline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Reactive Oxygen Species in Cancer: Current Findings and Future Directions
Nakamura, H., & Takada, K. (2021) · Cancer Science · doi:10.1111/cas.15068 · Cited by 1,027 · cited 1×
“Therefore, the coordination of ROS/redox homeostasis is pivotal for regulating physiological and pathological biological functions, including cell growth and survival, senescence, and aging [67,73].”
BackgroundTargeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003 · cited 2×
“tumorigenesis, TGF-β can act as a tumor suppressor; however, during cancer progression, TGF-β can activate cell growth, cancer progression, and dissemination through the promotion of epithelial-to-mesenchymal transition (EMT), angiogenesis, and escape from immune system [34].”
BackgroundLactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940
The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis
Hirayama, D., Iida, T., & Nakase, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010092 · Cited by 927 · cited 1×
“Physiologically, macrophages act via phagocytosis to destroy foreign antigens [30].”
BackgroundDonaldson, K., Murphy, F. A., Duffin, R., & Poland, C. A. (2010) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-7-5 · Cited by 916 · cited 1×
“may promote mesothelial cell transformation [78,79].”
Role of Glutathione in Cancer: From Mechanisms to Therapies
Kennedy, L., Sandhu, J. K., Harper, M.-E., & Cuperlovic-Culf, M. (2020) · Biomolecules · doi:10.3390/biom10101429 · Cited by 880 · cited 2×
“GSH is often overexpressed by cancer cells to overcome ROS accumulation [67,75] Cells also have catalytic antioxidants able to scavenge the superoxide anion O2·, converted into hydrogen peroxide (H2O2) by the cytosolic copper/zinc superoxide dismutases (SOD) 1 and 2, localized in the cytosol and mitochondria,”
BackgroundVégran, F., Boidot, R., Michiels, C., Sonveaux, P., & Feron, O. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2828 · Cited by 816
A New Group of Chromatin‐Associated Proteins with a High Content of Acidic and Basic Amino Acids
Goodwin, G. H., Sanders, C., & Johns, E. W. (1973) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1973.tb03026.x · Cited by 780 · cited 1×
“The HMGB1 protein is a member of the highly conserved non-histone DNA-binding protein family, so named for its characteristic rapid mobility in polyacrylamide gel electrophoresis [57].”
BackgroundHypoxia and Metabolic Adaptation of Cancer Cells
Eales, K. L., Hollinshead, K. E. R., & Tennant, D. A. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.50 · Cited by 724 · cited 3×
“Iron uptake is elevated and/or iron efflux is decreased, influenced by indirect or direct regulatory pathways [96,98].”
BackgroundSynnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N. A., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15337 · Cited by 679
Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215337 · Cited by 660
Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M., Karin, M., Goldrath, A. W., & Johnson, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1439 · Cited by 652
Metabolites and the Tumour Microenvironment: From Cellular Mechanisms to Systemic Metabolism
Elia, I., & Haigis, M. C. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00317-z · Cited by 651 · cited 2×
“This metabolic pathway, called the “Warburg effect” or aerobic glycolysis, protects cancer cells from hypoxic conditions and offers an abundant source of precursors for the synthesis of nucleic acids, phospholipids, and fatty acids, which is necessary for tumor cell proliferation [106,107].”
BackgroundInflammation as a Tumor Promoter in Cancer Induction
Philip, M., Rowley, D. A., & Schreiber, H. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.006 · Cited by 640 · cited 1×
“The activation of NF-κB stimulates cell growth and inhibits cell death, supporting cancer development [51].”
BackgroundIntegrative Molecular Characterization of Malignant Pleural Mesothelioma
Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0804 · Cited by 618 · cited 1×
“Furthermore, a study that explored 74 mesothelioma tumors using a genomic analysis identified TGF-β1 mRNA expression as being correlated with the worst patient prognoses [40].”
BackgroundSan-Millán, I., & Brooks, G. A. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw127 · Cited by 610
Orchestration of Metabolism by Macrophages
Biswas, S. K., & Mantovani, A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.013 · Cited by 586 · cited 1×
“In the tumor microenvironment, activated immune cells (T cells, dendritic cells, and macrophages) also undergo metabolic rewiring, switching between aerobic glycolysis and OXPHOS, depending on the microenvironmental conditions and state of activation [107,111,112].”
BackgroundRole of iron in carcinogenesis: cancer as a ferrotoxic disease
Toyokuni, S. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2008.01001.x · Cited by 552 · cited 1×
“Some studies have highlighted a role for the iron tumorigenic process induced by asbestos [18,99].”
BackgroundThe paradigm of IL-6: from basic science to medicine
Naka, T., Nishimoto, N., & Kishimoto, T. (2002) · Arthritis Research · doi:10.1186/ar565 · Cited by 547 · cited 1×
“IL-6 is a pleiotropic cytokine released by a plethora of cells, such as B cells, T cells, and macrophages, but also fibroblast, endothelial cells, and epidermal keratinocytes [43].”
BackgroundCancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
Romero-Garcia, S., Moreno-Altamirano, M. M. B., Prado-Garcia, H., & Sánchez-García, F. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00052 · Cited by 506
Reactive Oxygen Species in the Tumor Microenvironment: An Overview
Weinberg, F., Ramnath, N., & Nagrath, D. (2019) · Cancers · doi:10.3390/cancers11081191 · Cited by 502 · cited 4×
“The generation of ROS is increased in c ncer cells compared to ormal cells due to elevated energetic metabolic rates, gene mutatio s, and microenvironmental conditions such as hypoxia [68].”
BackgroundInfluentialYang, Q., Guo, N., Zhou, Y., Chen, J., Wei, Q., & Han, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.004 · Cited by 471 · cited 1×
“The activation of the CCL2/CCR2 axis, which mediates the crosstalk between tumor-associated macrophages (TAMs) and tumor cells, is associated with angiogenesis, metastases, immunosuppression, and cancer progression [27,28].”
BackgroundThe multifaceted role of reactive oxygen species in tumorigenesis
Kirtonia, A., Sethi, G., & Garg, M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03536-5 · Cited by 452 · cited 3×
“ROS play an essential role in carcinogenesis, affecting multiple biological processes, including genomic instability, cell growth, angiogenesis, inflammation, metabolic reprogramming, metastatization, and resistance to apoptosis [77].”
BackgroundInfluential(1997) · PubMed · Cited by 433
Torti, S. V., Manz, D. H., Paul, B. T., Blanchette-Farra, N., & Torti, F. M. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082117-051732 · Cited by 426 · cited 2×
“Therefore, iron shows a paradoxical role in tumors: iron is required by the cancer cell to sustain its growth and proliferation [93,95]; on the other hand, iron overload induces oxidative stress, producing many hydroxyl radicals, which can lead to lipid peroxidation.”
BackgroundKindler, H. L., Ismaila, N., Armato, S. G., Bueno, R., Hesdorffer, M., Jahan, T., Jones, C. M., Miettinen, M., Pass, H., Rimner, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6394 · Cited by 420 · cited 2×
“The use of surgery in patients with MPM is very limited, the only approved therapy regimen includes pemetrexed plus cisplatin, and there is no standard second-line treatment [3,4].”
BackgroundResultA Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385
Rhee, S. G., Yang, K.-S., Kang, S. W., Woo, H. A., & Chang, T.-S. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.619 · Cited by 376 · cited 1×
“H2O2 can then be converted by catalases (CATs), glutathione peroxidases (GPXs), or thioredoxin peroxidase (TrxP) into H2O and O2 [76].”
BackgroundMasquerader: High Mobility Group Box-1 and Cancer
Ellerman, J. E., Brown, C. K., de Vera, M., Zeh, H. J., Billiar, T., Rubartelli, A., & Lotze, M. T. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1953 · Cited by 355 · cited 1×
“HMGB1 overexpression has been observed in several neoplasms, such as breast cancer, pancreatic cancer, melanoma, and mesothelioma [60].”
BackgroundNovel Insights into Mesothelioma Biology and Implications for Therapy
Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.42 · Cited by 324 · cited 2×
“In turn, HMGB1 and pro-inflammatory cytokines promote the recruitment of macrophages and, together with ROS, sustain the chronic inflammatory process and DNA damage leading to mesothelial cell transformation over the years [1,21].”
BackgroundYang, H., Bocchetta, M., Kroczynska, B., Elmishad, A. G., Chen, Y., Liu, Z., Bubici, C., Mossman, B. T., Pass, H. I., Testa, J. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604008103 · Cited by 322
Jobling, M. F., Mott, J. D., Finnegan, M. T., Jurukovski, V., Erickson, A. C., Walian, P. J., Taylor, S. E., Ledbetter, S., Lawrence, C. M., Rifkin, D. B., et al. (2006) · Radiation Research · doi:10.1667/rr0695.1 · Cited by 300 · cited 1×
“It has been described that extracellular ROS regulate the TGF-β axis [66,84,85].”
BackgroundRuan, H.-B., Han, X., Li, M.-D., Singh, J. P., Qian, K., Azarhoush, S., Zhao, L., Bennett, A. M., Samuel, V. T., Wu, J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.07.006 · Cited by 296
HMGB1 in Inflammation and Cancer
Wang, S., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00950-x · Cited by 294 · cited 1×
“Stressed macrophages and mesothelial cells undergo cell necrosis, releasing the damage-associated molecular protein (DAMP) high mobility group box 1 (HMGB1) [20].”
BackgroundImmunosuppressive Activities of Adenosine in Cancer
Allard, B., Beavis, P. A., Darcy, P. K., & Stagg, J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.04.001 · Cited by 292
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1220 · Cited by 287
Yang, H., Rivera, Z., Jube, S., Nasu, M., Bertino, P., Goparaju, C., Franzoso, G., Lotze, M. T., Krausz, T., Pass, H. I., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006542107 · Cited by 281 · cited 11×
“This interaction induces another autocrine release of TNF-α by mesothelial cells, the activation of NF-κB signaling, and the final result of skipping the apoptotic process of the injured mesothelial cells [54].”
BackgroundInfluentialPopat, S., Curioni-Fontecedro, A., Dafni, U., Shah, R., O'Brien, M., Pope, A., Fisher, P., Spicer, J., Roy, A., Gilligan, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.009 · Cited by 271
Fennell, D. A., Ewings, S., Ottensmeier, C., Califano, R., Hanna, G. G., Hill, K., Danson, S., Steele, N., Nye, M., Johnson, L., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00471-x · Cited by 256
Krstić, J., Trivanović, D., Mojsilović, S., & Santibanez, J. F. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/654594 · Cited by 225
TGF-β Synergizes with Defects in the Hippo Pathway to Stimulate Human Malignant Mesothelioma Growth
Fujii, M., Toyoda, T., Nakanishi, H., Yatabe, Y., Sato, A., Matsudaira, Y., Ito, H., Murakami, H., Kondo, Y., Kondo, E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111653 · Cited by 224 · cited 1×
“As previously mentioned in this review, TGF-β itself and its family members have been recognized to be involved in cancer development [81], and TGF-β possesses a pro-oncogenic role in MPM connected to immune suppression [82,83].”
BackgroundMetabolic Barriers to T Cell Function in Tumors
Sugiura, A., & Rathmell, J. C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701041 · Cited by 208
(1987) · PubMed · Cited by 176
Role of Mutagenicity in Asbestos Fiber-Induced Carcinogenicity and Other Diseases
Huang, S. X. L., Jaurand, M.-C., Kamp, D. W., Whysner, J., & Hei, T. K. (2011) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2011.556051 · Cited by 163 · cited 1×
“Asbestos exposure is the most important risk factor in the formation of MPM, with a latency period of up to 40 years after exposure, even if the exact molecular mechanisms that explain its carcinogenicity are complex and not fully known [14,15].”
BackgroundEpithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor β
Tsubakihara, Y., & Moustakas, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113672 · Cited by 160 · cited 1×
“TGF-β1 plays a crucial role in promoting EMT, a key process involved in modulating alveolar epithelial cell plasticity [87,88].”
BackgroundThe Role of Iron in Cancer Progression
Guo, Q., Li, L., Hou, S., Yuan, Z., Li, C., Zhang, W., Zheng, L., & Li, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.778492 · Cited by 150 · cited 1×
“Several studies have shown that iron metabolism is involved in tumor occurrence and development [94].”
BackgroundAsbestos-Derived Reactive Oxygen Species Activate TGF-Β1
Pociask, D. A., Sime, P. J., & Brody, A. R. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700109 · Cited by 149
Novel therapies for malignant pleural mesothelioma
Scherpereel, A., Wallyn, F., Albelda, S. Μ., & Munck, C. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30100-1 · Cited by 149
Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Xu, J., Kadariya, Y., Cheung, M., Pei, J., Talarchek, J., Sementino, E., Tan, Y., Menges, C. W., Cai, K. Q., Litwin, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1328 · Cited by 144
Targeting tumor associated macrophages: The new challenge for nanomedicine
Andón, F. T., Digifico, E., Maeda, A., Erreni, M., Mantovani, A., Alonso, M. J., & Allavena, P. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.004 · Cited by 136
Schmitter, D., Lauber, B., Fagg, B., & Stahel, R. A. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510220 · Cited by 133 · cited 11×
“High levels of IL-6 have been also revealed in patients’ pleural fluids [47].”
BackgroundInfluentialGermline BAP1 mutations induce a Warburg effect
Bononi, A., Yang, H., Giorgi, C., Patergnani, S., Pellegrini, L., Su, M., Xie, G., Signorato, V., Pastorino, S., Morris, P., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.95 · Cited by 133
Tumor-Derived Adenosine Promotes Macrophage Proliferation in Human Hepatocellular Carcinoma
Wang, J., Wang, Y., Chu, Y., Li, Z., Yu, X., Huang, Z., Xu, J., & Zheng, L. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.10.021 · Cited by 133
The Multifaceted Role of Heme in Cancer
Fiorito, V., Chiabrando, D., Petrillo, S., Bertino, F., & Tolosano, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01540 · Cited by 129 · cited 1×
“Therefore, iron shows a paradoxical role in tumors: iron is required by the cancer cell to sustain its growth and proliferation [93,95]; on the other hand, iron overload induces oxidative stress, producing many hydroxyl radicals, which can lead to lipid peroxidation.”
BackgroundEmerging Roles for HMGB1 Protein in Immunity, Inflammation, and Cancer
Ranzato, E., Martinotti, S., & Patrone, M. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s58064 · Cited by 127 · cited 3×
“HMGB1 is actively secreted by endothelial cells, immune cells, neurons, platelets, astrocytes, and tumor cells during stress conditions, or secondary to other DAMP danger signals as support [58].”
BackgroundInfluentialMacrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk
Sarode, P., Schaefer, M. B., Grimminger, F., Seeger, W., & Savai, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00324 · Cited by 123
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma
Zauderer, M. G., Kass, S. L., Woo, K. M., Sima, C. S., Ginsberg, M. S., & Krug, L. M. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.006 · Cited by 117 · cited 1×
“As a second-line treatment [3,10], preliminary uncontrolled trials of ICIs have suggested encouraging activity, but with contrasting results in terms of survival improvement in different clinical studies [11,12].”
ResultCirculating and Tumor-Infiltrating Myeloid Cells Predict Survival in Human Pleural Mesothelioma
Burt, B. M., Rodig, S. J., Tilleman, T. R., Elbardissi, A. W., Bueno, R., & Sugarbaker, D. J. (2011) · Cancer · doi:10.1002/cncr.26143 · Cited by 115 · cited 1×
“A huge number of infiltrating M2-like macrophages (CD163+; CD206+; and IL-4Rα+) have been found in MPM [24,29].”
BackgroundInterleukin-6 Induces Both Cell Growth and VEGF Production in Malignant Mesotheliomas
Adachi, Y., Aoki, C., Yoshio‐Hoshino, N., Takayama, K., Curiel, D. T., & Nishimoto, N. (2006) · International Journal of Cancer · doi:10.1002/ijc.22006 · Cited by 115 · cited 1×
“Despite these observations, other authors [48] have concluded that IL-6 can play a putative role as an autocrine molecule via a signal transducer activator of the transcription 3 (STAT3) pathway.”
BackgroundSuzuki, E., Kim, S., Cheung, H.-K., Corbley, M. J., Zhang, X., Sun, L., Shan, F., Singh, J., Lee, W.-C., Albelda, S. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2389 · Cited by 113 · cited 1×
“Notably, TGF-β pathway blocking can lead to a substantial inhibition of the in vivo growth of mesothelioma [39].”
BackgroundHow Asbestos and Other Fibers Cause Mesothelioma
Gaudino, G., Xue, J., & Yang, H. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.02.01 · Cited by 102
Betti, M., Casalone, E., Ferrante, D., Aspesi, A., Morleo, G., Biasi, A., Sculco, M., Mancuso, G., Guarrera, S., Righi, L., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.028 · Cited by 101 · cited 1×
“Many genetic factors can influence MPM carcinogenesis and outcomes, such as mutations in tumor suppressor genes such as cyclin dependent kinase inhibitor 2A (CDKN2A), BRCA1 associated protein 1 (BAP1), neurofibromatosis 2 (NF2), and TP53 [8,17].”
BackgroundReactive Oxygen Species a Double-Edged Sword for Mesothelioma
Benedetti, S., Nuvoli, B., Catalani, S., & Galati, R. (2015) · Oncotarget · doi:10.18632/oncotarget.4253 · Cited by 97 · cited 2×
“may promote mesothelial cell transformation [78,79].”
BackgroundCarbone, M., Pass, H. I., Ak, G., Alexander, H. R., Baas, P., Baumann, F., Blakely, A. M., Bueno, R., Bzura, A., Cardillo, G., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.03.014 · Cited by 97
Songür, N., Kuru, B., Kalkan, F., Özdilekcan, Ç., Çakmak, H., & Hızel, N. (2004) · Tumori Journal · doi:10.1177/030089160409000207 · Cited by 96
Toyokuni, S. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.401 · Cited by 96 · cited 1×
“Finally, it has been reported that iron-catalyzed ROS production and impaired ferroptosis may be involved in asbestos-related carcinogenesis [102].”
BackgroundHuebener, P., Gwak, G.-Y., Pradere, J.-P., Quinzii, C. M., Friedman, R., Lin, C.-S., Trent, C. M., Mederacke, I., Zhao, E., Dapito, D. H., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.014 · Cited by 86 · cited 1×
“Cytoplasmic HMGB1 is involved in immune responses by inhibiting apoptosis, increasing autophagy, and regulating mitochondrial functions [59].”
BackgroundAsbestos Surface Provides a Niche for Oxidative Modification
Nagai, H., Ishihara, T., Lee, W., Ohara, H., Okazaki, Y., Okawa, K., & Toyokuni, S. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02087.x · Cited by 86 · cited 3×
“Some studies have highlighted a role for the iron tumorigenic process induced by asbestos [18,99].”
BackgroundNew Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options
Tsao, A. S., Pass, H. I., Rimner, A., & Mansfield, A. S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01567 · Cited by 86
Stevenson, J. P., Kindler, H. L., Papasavvas, E., Sun, J., Jacobs-Small, M., Hull, J., Schwed, D., Ranganathan, A., Newick, K., Heitjan, D. F., et al. (2013) · OncoImmunology · doi:10.4161/onci.26218 · Cited by 85 · cited 1×
“According to these data on the role of TGF-β, fresolimumab, a human anti-transforming growth factor-beta monoclonal antibody, has been tested in patients with advanced mesothelioma [41].”
BackgroundChéné, A.-L., d’Almeida, S., Blondy, T., Tabiasco, J., Deshayes, S., Fonteneau, J.-F., Cellerin, L., Delneste, Y., Grégoire, M., & Blanquart, C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.022 · Cited by 84
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Nicolini, F., Bocchini, M., Bronte, G., Delmonte, A., Guidoboni, M., Crinò, L., & Mazza, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01519 · Cited by 83 · cited 1×
“Many genetic factors can influence MPM carcinogenesis and outcomes, such as mutations in tumor suppressor genes such as cyclin dependent kinase inhibitor 2A (CDKN2A), BRCA1 associated protein 1 (BAP1), neurofibromatosis 2 (NF2), and TP53 [8,17].”
BackgroundShi, L., Wu, Z., Miao, J., Du, S., Ai, S., Xu, E., Feng, M., Song, J., & Guan, W. (2019) · Molecular Biology of the Cell · doi:10.1091/mbc.e19-03-0136 · Cited by 79
Clinical Significance of Histologic Subtyping of Malignant Pleural Mesothelioma
Brcic, L., & Kern, I. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.38 · Cited by 77 · cited 1×
“On the contrary, the sarcomatoid subtype (25% of cases) is associated with a poor prognosis [16].”
BackgroundNeuCode Proteomics Reveals Bap1 Regulation of Metabolism
Baughman, J. M., Rose, C. M., Kolumam, G., Webster, J. D., Wilkerson, E. M., Merrill, A. E., Rhoads, T. W., Noubade, R., Katavolos, P., Lesch, J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.096 · Cited by 73
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Chu, G. J., van Zandwijk, N., & Rasko, J. E. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01366 · Cited by 70 · cited 2×
“The onset of mesothelioma is associated with exposure to asbestos, and consequently, the activation of immune system cells in the surrounding tissue/TME, leading to oxidative stress with ROS release and the secretion of pro-inflammatory factors amplifying the process of inflammation [22].”
BackgroundMinato, H., Kurose, N., Fukushima, M., Nojima, T., Usuda, K., Sagawa, M., Sakuma, T., Ooi, A., Matsumoto, I., Oda, M., et al. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcp5knl7qtellyi · Cited by 67
Tumor‑associated macrophages in lung cancer: Friendly or evil? (Review)
Xu, F., Wei, Y., Tang, Z., Liu, B., & Dong, J. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11518 · Cited by 67 · cited 1×
“The activation of the CCL2/CCR2 axis, which mediates the crosstalk between tumor-associated macrophages (TAMs) and tumor cells, is associated with angiogenesis, metastases, immunosuppression, and cancer progression [27,28].”
BackgroundByun, H.-O., Jung, H.-J., Seo, Y.-H., Lee, Y.-K., Hwang, S.-C., Seong Hwang, E., & Yoon, G. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.04.012 · Cited by 66
Suzuki, E., Kapoor, V., Cheung, H.-K., Ling, L. E., DeLong, P. A., Kaiser, L. R., & Albelda, S. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0611 · Cited by 65 · cited 1×
“As previously mentioned in this review, TGF-β itself and its family members have been recognized to be involved in cancer development [81], and TGF-β possesses a pro-oncogenic role in MPM connected to immune suppression [82,83].”
Background(1994) · PubMed · Cited by 65
Aung, W., Hasegawa, S., Furukawa, T., & Saga, T. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm090 · Cited by 62 · cited 7×
“GSH is often overexpressed by cancer cells to overcome ROS accumulation [67,75] Cells also have catalytic antioxidants able to scavenge the superoxide anion O2·, converted into hydrogen peroxide (H2O2) by the cytosolic copper/zinc superoxide dismutases (SOD) 1 and 2, localized in the cytosol and mitochondria, Cells 20…”
BackgroundInfluentialBetti, M., Aspesi, A., Ferrante, D., Sculco, M., Righi, L., Mirabelli, D., Napoli, F., Rondón‐Lagos, M., Casalone, E., Vignolo Lutati, F., et al. (2018) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22670 · Cited by 62
Yamagishi, T., Fujimoto, N., Nishi, H., Miyamoto, Y., Hara, N., Asano, M., Fuchimoto, Y., Wada, S., Kitamura, K., Ozaki, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.07.014 · Cited by 61 · cited 1×
“In contrast, the LMR has been recognized as an independent prognostic marker for survival in patients, and the LMR is superior to other inflammation-based prognostic scores [64].”
BackgroundImmunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58
Diagnosis and Prognosis-Review of Biomarkers for Mesothelioma
Sun, H. H., Vaynblat, A., & Pass, H. I. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.60 · Cited by 55
Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases
Ying, S., Jiang, Z., He, X., Yu, M., Chen, R., Chen, J., Ru, G., Chen, Y., Chen, W., Zhu, L., et al. (2017) · Disease Markers · doi:10.1155/2017/5756102 · Cited by 54 · cited 2×
“High levels in the blood of both subjects exposed to asbestos and mesothelioma patients have been demonstrated [62].”
BackgroundKlabatsa, A., Sheaff, M. T., Steele, J. P. C., Evans, M. T., Rudd, R. M., & Fennell, D. A. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2005.07.010 · Cited by 53
Fujii, M., Nakanishi, H., Toyoda, T., Tanaka, I., Kondo, Y., Osada, H., & Sekido, Y. (2012) · Cell Cycle · doi:10.4161/cc.21397 · Cited by 53 · cited 1×
“In mesothelioma, some TGF-β family members, such as gremlin-1 [35], activin A [36], and TGF-β itself [37], have been recognized as being involved in cancer development.”
BackgroundInterleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon ? immunotherapy
Bielefeldt-Ohmann, H., Marzo, A. L., Himbeck, R. P., Jarnicki, A. G., Robinson, B. W. S., & Fitzpatrick, D. R. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01519898 · Cited by 52
Hypoxia Promotes Acquisition of Aggressive Phenotypes in Human Malignant Mesothelioma
Kim, M.-C., Hwang, S.-H., Kim, N.-Y., Lee, H.-S., Ji, S., Yang, Y., & Kim, Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4720-z · Cited by 49 · cited 3×
“In summary, hypoxia raises the acquisition of aggressive phenotypes in human malignant mesothelioma, also supporting metabolic plasticity [113].”
BackgroundMetabolic Rewiring and Redox Alterations in Malignant Pleural Mesothelioma
Urso, L., Cavallari, I., Sharova, E., Ciccarese, F., Pasello, G., & Ciminale, V. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0661-9 · Cited by 47 · cited 6×
“Mesothelioma cells show a metabolic plasticity [66] (Figure 2).”
BackgroundInfluentialStabilization of MCRS1 by BAP1 Prevents Chromosome Instability in Renal Cell Carcinoma
Peng, J., Ma, J., Li, W., Mo, R., Zhang, P., Gao, K., Jin, X., Xiao, J., Wang, C., & Fan, J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.08.013 · Cited by 46
Ramundo, V., Zanirato, G., & Aldieri, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212216 · Cited by 46
Turini, S., Bergandi, L., Gazzano, E., Prato, M., & Aldieri, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010150 · Cited by 44 · cited 6×
“This phenotypic plasticity is mediated by the over-expression of TGF-β1 [90].”
BackgroundInfluential(2011) · PubMed · Cited by 41
Zolondick, A. A., Gaudino, G., Xue, J., Pass, H. I., Carbone, M., & Yang, H. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-21-12 · Cited by 41
Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
Cersosimo, F., Barbarino, M., Lonardi, S., Vermi, W., Giordano, A., Bellan, C., & Giurisato, E. (2021) · Cancers · doi:10.3390/cancers13225664 · Cited by 41 · cited 2×
“AP in cancer cells by increasing the secretion of cytokines and immune modulatory factors, including IL6, IL10, TGFβ, and VEGF, and activating survival/signaling pathways such as PI3K-AktmTOR, sustains immunosuppression and promotes tumor progression, metastasis, and therapy resistance [26,129,130].”
BackgroundZoledronic Acid Overcomes Chemoresistance and Immunosuppression of Malignant Mesothelioma
Salaroglio, I. C., Campia, I., Kopecka, J., Gazzano, E., Orecchia, S., Ghigo, D., & Riganti, C. (2015) · Oncotarget · doi:10.18632/oncotarget.2731 · Cited by 36
Characterization of Hypoxia in Malignant Pleural Mesothelioma with FMISO PET-CT
Francis, R. J., Segard, T., Morandeau, L., Lee, Y. C. G., Millward, M. J., Segal, A., & Nowak, A. K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.07.015 · Cited by 34
PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial
Fennell, D., Ottensmeier, C., Califano, R., Hanna, G., Ewings, S., Hill, K., Wilding, S., Danson, S., Nye, M., Steele, N., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.323 · Cited by 34 · cited 1×
“As a second-line treatment [3,10], preliminary uncontrolled trials of ICIs have suggested encouraging activity, but with contrasting results in terms of survival improvement in different clinical studies [11,12].”
ResultThe Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021) · Cancers · doi:10.3390/cancers13133205 · Cited by 34
Gremlin-1 Is a Key Regulator of the Invasive Cell Phenotype in Mesothelioma
Yin, M., Tissari, M., Tamminen, J., Ylivinkka, I., Rönty, M., von Nandelstadh, P., Lehti, K., Hyytiäinen, M., Myllärniemi, M., & Koli, K. (2017) · Oncotarget · doi:10.18632/oncotarget.21550 · Cited by 33 · cited 1×
“In mesothelioma, some TGF-β family members, such as gremlin-1 [35], activin A [36], and TGF-β itself [37], have been recognized as being involved in cancer development.”
BackgroundThe Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer
Cheng, Y. Y., Rath, E. M., Linton, A., Yuen, M. L., Takahashi, K., & Lee, K. (2020) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s186843 · Cited by 31 · cited 1×
“However, recent studies have proposed that NLR elevation could be a potential prognostic factor for mesothelioma patients [63].”
BackgroundBiological Basis for Novel Mesothelioma Therapies
Obacz, J., Yung, H., Shamseddin, M., Linnane, E., Liu, X., Azad, A. A., Rassl, D. M., Fairen-Jimenez, D., Rintoul, R. C., Nikolić, M. Z., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01462-2 · Cited by 31
Iron Metabolism: State of the Art in Hypoxic Cancer Cell Biology
Liu, S., Cao, X., Wang, D., & Zhu, H. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109199 · Cited by 31 · cited 1×
“Iron uptake is elevated and/or iron efflux is decreased, influenced by indirect or direct regulatory pathways [96,98].”
BackgroundHoda, M. A., Dong, Y., Rozsas, A., Klikovits, T., Laszlo, V., Ghanim, B., Stockhammer, P., Ozsvar, J., Jakopovic, M., Samarzija, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.018 · Cited by 27 · cited 1×
“In mesothelioma, some TGF-β family members, such as gremlin-1 [35], activin A [36], and TGF-β itself [37], have been recognized as being involved in cancer development.”
BackgroundStockhammer, P., Plönes, T., Theegarten, D., Schüler, M., Maier, S. M., Aigner, C., & Hegedűs, B. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.013 · Cited by 26 · cited 1×
“However, new findings [42] on the suitability of TGF-β level, using pleural effusions as a reliable diagnostic biomarker, may pave the way to further understanding TGF-β’s role in the pleural space.”
BackgroundAsbestos Exposure Induces Alveolar Epithelial Cell Plasticity through MAPK/Erk Signaling
Tamminen, J. A., Myllärniemi, M., Hyytiäinen, M., Keski‐Oja, J., & Koli, K. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24094 · Cited by 25 · cited 1×
“TGF-β1 plays a crucial role in promoting EMT, a key process involved in modulating alveolar epithelial cell plasticity [87,88].”
BackgroundAutocrine and Paracrine Purinergic Signaling in the Most Lethal Types of Cancer
Reyna-Jeldes, M., Díaz-Muñoz, M., Madariaga, J. A., Coddou, C., & Vázquez-Cuevas, F. G. (2021) · Purinergic Signalling · doi:10.1007/s11302-021-09785-8 · Cited by 25
(2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2015.11.15 · Cited by 24 · cited 1×
“PLR was identified as an independent prognostic factor in mesothelioma patients, representing a new scoring system for predicting disease outcomes [65].”
BackgroundHommell-Fontaine, J., Isaac, S., Passot, G., Decullier, E., Traverse-Glehen, A., Cotte, E., You, B., Mohamed, F., Gilly, F. N., Glehen, O., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3077-4 · Cited by 23
Inflammatory Cytokines Contribute to Asbestos-Induced Injury of Mesothelial Cells
Acencio, M. M. P., Soares, B., Marchi, E., Silva, C. S. R., Teixeira, L. R., & Broaddus, V. C. (2015) · Lung · doi:10.1007/s00408-015-9744-4 · Cited by 23 · cited 1×
“Asbestos fibers damage the integrity of the mesothelial tissue, provoking a local inflammation process with the overproduction of free radicals and release of pro-inflammatory cytokines [52].”
BackgroundAsbestos: Modern Insights for Toxicology in the Era of Engineered Nanomaterials
Felley-Bosco, E., & MacFarlane, M. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00146 · Cited by 23
Napoli, F., Listì, A., Zambelli, V., Witel, G., Bironzo, P., Papotti, M., Volante, M., Scagliotti, G., & Righi, L. (2021) · Cancers · doi:10.3390/cancers13112564 · Cited by 22
Tanaka, H., Sun, T., Kinashi, H., Kamiya, K., Yamaguchi, M., Nobata, H., Sakata, F., Kim, H., Mizuno, M., Kunoki, S., et al. (2022) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00396.2021 · Cited by 22 · cited 1×
“IL-6 is a soluble mediator exerting a pleiotropic effect on the immune response, inflammation, and hematopoiesis [44].”
BackgroundOutcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression.
Rivalland, G., Kao, S., Pavlakis, N., Hughes, B. G. M., Thapa, B., Pal, A., Walkiewicz, M., Zimet, A. S., White, S. C., O'Byrne, K. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.8514 · Cited by 21 · cited 1×
“Many efforts are ongoing to find predictive factors that can help to select the suitable candidate patients for immunotherapy [2,13].”
BackgroundNew chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production
McLaren, B. R., Robinson, B. W. S., & Lake, R. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051026 · Cited by 17 · cited 1×
“However, IL-6 is worthy of investigation, because it is emerging as a possible resistance mediator to classic cytotoxicity agents [50].”
BackgroundAl-Taei, S., Salimu, J., Spary, L. K., Clayton, A., Lester, J. F., & Tabi, Z. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1268308 · Cited by 17
Expression analysis of HMGB 1 in histological samples of malignant pleural mesothelioma
Rrapaj, E., Trisolini, E., Bertero, L., Salvo, M., Indellicato, R., Andorno, S., Garcia‐Manteiga, J. M., Rena, O., & Boldorini, R. L. (2018) · Histopathology · doi:10.1111/his.13470 · Cited by 17 · cited 1×
“HMGB1 also appears to be correlated with malignant mesothelioma [61,62].”
BackgroundAcute Myeloid Leukaemia Drives Metabolic Changes in the Bone Marrow Niche
Maynard, R. S., Hellmich, C., Bowles, K. M., & Rushworth, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924567 · Cited by 17 · cited 1×
“Usually, cancer cells increase the rate of glycolysis, leading to a massive conversion of the pyruvate in lactate, a sort of fermentation, but in the presence of oxygen [105].”
BackgroundNakajima, Y., Kuribayashi, K., Ishigaki, H., Tada, A., Negi, Y., Minami, T., Takahashi, R., Doi, H., Kitajima, K., Yokoi, T., et al. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1776313 · Cited by 13
Tedesco, J., Jaradeh, M., & Vigneswaran, W. T. (2022) · Cancers · doi:10.3390/cancers14184415 · Cited by 12
Kambara, T., Amatya, V., Kushitani, K., Fujii, Y., Endo, I., & Takeshima, Y. (2022) · Oncology Letters · doi:10.3892/ol.2022.13294 · Cited by 9 · cited 1×
“The other subunit of ferritin, the ferritin light chain (FTL), is able to affect p27, p21, cyclindependent kinase 2 (CDK2), and retinoblastoma protein (pRB) expression, increasing the proliferative capacity of malignant mesothelioma cells and promoting the cell cycle [101].”
BackgroundGrowth factor production by normal human mesothelial cells and mesothelioma cell lines
Gerwin, B. I., Lechner, J. F., Reddel, R. R., Betsholtz, C., Roberts, A., & Harris, C. C. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90552-9 · Cited by 9
The Usefulness of Biomarkers in Diagnosis of Asbestos-Induced Malignant Pleural Mesothelioma
Tanrıverdi, Z., Meteroglu, F., Yüce, H., Şenyiğit, A., Işcan, M., & Unüvar, S. (2021) · Human & Experimental Toxicology · doi:10.1177/09603271211017324 · Cited by 7
Cited by
ROS: A “booster” for chronic inflammation and tumor metastasis
Chen, A., Huang, H., Fang, S., & Hang, Q. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189175 · Cited by 151
Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities
Wang, M., Xiao, Y., Miao, J., Zhang, X., Liu, M., Zhu, L., Liu, H., Shen, X., Wang, J., Xie, B., et al. (2025) · Antioxidants · doi:10.3390/antiox14060735 · Cited by 124
Macrophages: Subtypes, Distribution, Polarization, Immunomodulatory Functions, and Therapeutics
Peng, M., Li, N., Wang, H., Li, Y., Liu, H., Luo, Y., Lang, B., Zhang, W., Li, S., Tian, L., et al. (2025) · MedComm · doi:10.1002/mco2.70304 · Cited by 121
“The CSF-1/IL-34–CSF-1R pathway is also related to chronic inflammation, oxidative stress, ROS generation, and sustained abnormal signal transduction [179]; thus, regulation of CSF-1R may hold promise for the treatment of chronic inflammatory diseases [180].”
Mesothelial and immune cells interplay in the tumor microenvironment
Sheng, R., Yin, Y., & Wang, X. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.03.014 · Cited by 19
Alkaptonuria: From Molecular Insights to a Dedicated Digital Platform
Milella, M. S., Geminiani, M., Trezza, A., Visibelli, A., Braconi, D., & Santucci, A. (2024) · Cells · doi:10.3390/cells13121072 · Cited by 16
“Oxidative Stress, Chronic Inflammation, and Secondary (AA) Amyloidosis in Rheumatic Diseases Oxidative stress and inflammation are common players in rheumatic diseases such as osteoarthritis (OA) [9,22,23] and rheumatoid arthritis (RA) [24–26].”
Background
Metadata
- Authors
- Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V.
- Affiliations
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Corresponding author
- Audrito, Valentina
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-08-11
- Volume
- 12
- Issue
- 16
- Pages
- 2048
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC10453755
- OpenAlex
- W4385759859
- Cited by
- 39
- References
- 158
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 10
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- the Associazione Italiana di Ricerca sul Cancro (MFAG-2021 #26004)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- malignant pleural mesothelioma, asbestos exposure, chronic inflammation, oxidative stress, reactive oxygen species, tumor microenvironment, metabolic plasticity, tumor hypoxia, tumor-associated macrophages, damage-associated molecular patterns, antitumor immunity, metabolic crosstalk, tumor progression, therapeutic target
- MeSH terms
- Mesothelioma, Malignant, Humans, Inflammation, Reactive Oxygen Species, Oxidative Stress, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.